Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
30.00
-0.50 (-1.64%)
At close: Mar 6, 2026, 4:00 PM EST
29.21
-0.79 (-2.63%)
After-hours: Mar 6, 2026, 7:07 PM EST
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
37.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 151.93M |
| Xilio Therapeutics | 31.80M |
| Veru Inc. | 16.89M |
| NovaBay Pharmaceuticals | 10.30M |
| CervoMed | 6.16M |
| Lisata Therapeutics | 1.07M |
| Actinium Pharmaceuticals | 90.00K |
SNSE News
- 10 days ago - Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire
- 2 months ago - Egle Therapeutics Appoints John Celebi as Chief Executive Officer - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 - GlobeNewsWire
- 6 months ago - Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire